BSA-Based Stabilization of Prussian Blue-Coated Manganese Ferrite Nanoparticles for MRI
Objectives: Magnetic nanoparticles are promising candidates for T2-weighted magnetic resonance imaging (MRI), but their physicochemical stability and biological compatibility remain important challenges for biomedical applications. Methods: In this study, amine-functionalized manganese ferrite (MnFe2O4) nanoparticles were coated with Prussian blue (PB) and subsequently formulated with bovine serum albumin (BSA). The resulting formulation was characterized using X-ray diffraction, transmission electron microscopy, X-ray photoelectron spectroscopy, Fourier-transform infrared spectroscopy, magnetic measurements, dynamic light scattering, molecular dynamics simulations, cytocompatibility assays, and MRI relaxometry. Results: The BSA-formulated nanoparticles were readily redispersed after lyophilization and remained colloidally stable throughout the 6 h observation period in the tested aqueous media. Molecular dynamics simulations demonstrated persistent close contacts between the MnFe2O4 surface and BSA residues, supporting stable nanoparticle–protein association. MRI relaxometry showed predominantly T2-weighted contrast behavior, with substantially higher r2 than r1 relaxivity. In vitro metabolic activity measurements demonstrated higher relative metabolic activity for the PB-coated formulation than for the corresponding uncoated formulation within the BSA-formulated systems. A pilot in vivo MRI experiment performed in a single mouse demonstrated rapid hepatic accumulation, with a detectable reduction in liver signal intensity within 10 min after administration and persistence of the hepatic signal change at the following-day measurement. Conclusions: These preliminary findings support further investigation of BSA-formulated PB-coated MnFe2O4 nanoparticles as a potential T2-weighted MRI contrast platform.
Authors
- Krisztián Szigeti (ORCID: https://orcid.org/0000-0002-0828-9828)
- Miklós Németh (ORCID: https://orcid.org/0000-0003-2236-8159)
- Béla Viskolcz (ORCID: https://orcid.org/0000-0002-0777-9569)
- Ágnes Mária Ilosvai
- Ferenc Kristály (ORCID: https://orcid.org/0000-0002-0075-5994)
- László Forgách (ORCID: https://orcid.org/0000-0001-6089-9124)
- Fatemeh Heydari (ORCID: https://orcid.org/0009-0002-8002-5007)
- Babak Minofar (ORCID: https://orcid.org/0000-0001-8096-2194)
- Lajos Daróczi (ORCID: https://orcid.org/0000-0002-9374-5225)
- László Vanyorek (ORCID: https://orcid.org/0000-0002-0630-0595)
- Tamás Ollár (ORCID: https://orcid.org/0000-0001-8072-7928)
- Noémi Kovács
- David Reha
Institutions
- Semmelweis University (HU)
- University of Debrecen (HU)
- VSB - Technical University of Ostrava (CZ)
- University of Miskolc (HU)
- University of Łódź (PL)
- HUN-REN Centre for Energy Research (HU)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2026-09-24
- DOI
- https://doi.org/10.3390/pharmaceutics18101217
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00